YTHDF2 inhibition potentiates radiotherapy antitumor efficacy
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Abstract
Summary RNA N6-methyladenosine (m6A) modification is implicated in cancer progression. However, the impact of m6A on the anti-tumor effects of radiotherapy and the related mechanisms are unknown. Here we show that ionizing radiation (IR) induces immunosuppressive myeloid-derived suppressor cell (MDSC) expansion and YTHDF2 expression in both murine models and humans. Following IR, loss of Ythdf2 in myeloid cells augments antitumor immunity and overcomes tumor radioresistance by altering MDSC differentiation, and inhibiting MDSC infiltration and suppressive function. The remodeling of the landscape of MDSC populations by local IR is reversed by Ythdf2 deficiency. IR-induced YTHDF2 expression relies on NF-κB signaling; YTHDF2 in turn leads to NF-κB activation by directly binding and degrading transcripts encoding negative regulators of NF-κB signaling, resulting in an IR-YTHDF2-NF-κB circuit. Pharmacological inhibition of YTHDF2 overcomes MDSC-induced immunosuppression and improves combined IR and/or anti-PD-L1 treatment. Thus, YTHDF2 is a promising target to improve radiotherapy (RT) and RT/immunotherapy combinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464 · cited 1×
“Reads, from input of m 6 A-seq or YTHFDF2 RIP-seq, on each GENCODE annotated gene were counted using HTSeq 89 and then differentially expressed genes were called using DESeq2 package in R 90 requiring at least 10 read counts in at least three samples with adjusted p-value 0.05.”
InfluentialModel-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Twelve years of SAMtools and BCFtools
Danecek, P., Bonfield, J. K., Liddle, J., Marshall, J., Ohan, V., Pollard, M. O., Whitwham, A., Keane, T., McCarthy, S. A., Davies, R. M., et al. (2021) · GigaScience · doi:10.1093/gigascience/giab008 · Cited by 15,343
Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype
Kim, D., Paggi, J. M., Park, C., Bennett, C., & Salzberg, S. L. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0201-4 · Cited by 15,022
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 1×
“16,17 Mechanisms of immune suppression by MDSCs include secretion or expression of immunoregulatory factors, 18,19 which downregulate cytotoxic CD8 + T cell function.”
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593 · cited 1×
“12,13 These trials utilized checkpoint blockade after chemo/ radiotherapy to inhibit microscopic metastatic disease, however a consistent meaningful interaction between checkpoint immunotherapy and radiotherapy in humans has yet to be established.”
Self-citationN6-methyladenosine-dependent regulation of messenger RNA stability
Wang, X., Lu, Z., Gomez, A., Hon, G. C., Yue, Y., Han, D., Fu, Y., Parisien, M., Dai, Q., Jia, G., et al. (2014) · Nature · doi:10.1038/nature12730 · Cited by 4,558
Self-citationMcGinnis, C. S., Murrow, L. M., & Gartner, Z. J. (2019) · Cell Systems · doi:10.1016/j.cels.2019.03.003 · Cited by 4,521
Visualizing and interpreting cancer genomics data via the Xena platform
Goldman, M. J., Craft, B., Hastie, M., Repečka, K., McDade, F., Kamath, A., Banerjee, A., Luo, Y., Rogers, D., Brooks, A. N., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0546-8 · Cited by 4,481
N6-methyladenosine Modulates Messenger RNA Translation Efficiency
Wang, X., Zhao, B. S., Roundtree, I. A., Lu, Z., Han, D., Ma, H., Weng, X., Chen, K., Shi, H., & He, C. (2015) · Cell · doi:10.1016/j.cell.2015.05.014 · Cited by 3,483 · cited 1×
“42,44 45–49 Only few studies have reached the impact of reader proteins on antitumor immune response: loss of Ythdf1 enhanced the cross-priming activity via decreasing lysosomal proteases in classical dendritic cells and suppressed tumor growth.”
Self-citationDynamic RNA Modifications in Gene Expression Regulation
Roundtree, I. A., Evans, M. E., Pan, T., & He, C. (2017) · Cell · doi:10.1016/j.cell.2017.05.045 · Cited by 3,399 · cited 1×
“41 Among the m 6 A reader proteins, YTHDF1 facilitates mRNA translation; YTHDF2 promotes mRNA degradation; and YTHDF3 promotes both translation and RNA degradation depending on the biological context.”
Self-citationThe prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,118
The NF- B Family of Transcription Factors and Its Regulation
Oeckinghaus, A., & Ghosh, S. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000034 · Cited by 2,842 · cited 1×
“64 We next analyzed a public dataset of RELA chromatin immunoprecipitation sequencing (ChIP-seq) conducted in mouse bone marrow-derived macrophages and found the predicted direct binding between RELA and the Ythdf2 promoter region (Figure S4F).”
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263 · cited 1×
“4 9 Encouraged by these promising preclinical results, an increasing number of clinical trials combining checkpoint blockade with IR has been launched (reviewed in 10,11 ).”
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J., Motoyama, S., Lièvre, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032125 · Cited by 1,827 · cited 1×
“12,13 These trials utilized checkpoint blockade after chemo/ radiotherapy to inhibit microscopic metastatic disease, however a consistent meaningful interaction between checkpoint immunotherapy and radiotherapy in humans has yet to be established.”
YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA
Shi, H., Wang, X., Lu, Z., Zhao, B. S., Ma, H., Hsu, P. J., Liu, C., & He, C. (2017) · Cell Research · doi:10.1038/cr.2017.15 · Cited by 1,815 · cited 1×
“42,44 45–49 Only few studies have reached the impact of reader proteins on antitumor immune response: loss of Ythdf1 enhanced the cross-priming activity via decreasing lysosomal proteases in classical dendritic cells and suppressed tumor growth.”
Self-citationSingle-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer
Zhang, L., Li, Z., Skrzypczynska, K. M., Fang, Q., Zhang, W., O’Brien, S. A., He, Y., Wang, L., Zhang, Q., Kim, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.048 · Cited by 1,526
Self-citationZhang, S., Zhao, B. S., Zhou, A., Lin, K., Zheng, S., Lu, Z., Chen, Y., Sulman, E. P., Xie, K., Bögler, O., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.013 · Cited by 1,459 · cited 1×
“42,44 45–49 Only few studies have reached the impact of reader proteins on antitumor immune response: loss of Ythdf1 enhanced the cross-priming activity via decreasing lysosomal proteases in classical dendritic cells and suppressed tumor growth.”
Self-citationSmall-molecule inhibition of METTL3 as a strategy against myeloid leukaemia
Yankova, E., Blackaby, W., Albertella, M., Rak, J., De Braekeleer, E., Tsagkogeorga, G., Pilka, E. S., Aspris, D., Leggate, D., Hendrick, A. G., et al. (2021) · Nature · doi:10.1038/s41586-021-03536-w · Cited by 1,352 · cited 1×
“We concede that DC-Y13-27 is a tool compound that only showing high selectivity, which is similar to one published m 6 A-assosicated inhibitor (METTL13 inhibitor, STM2457) 77 .”
Lee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324
Self-citationRNA modifications modulate gene expression during development
Frye, M., Harada, B. T., Behm, M., & He, C. (2018) · Science · doi:10.1126/science.aau1646 · Cited by 1,249 · cited 1×
“39,40 m 6 A is dynamically regulated by “writers” (methyltransferase complex: METTL3, METTL14, and WTAP) that install m 6 A methylation; “erasers” (demethylases: FTO and ALKBH5) that remove m 6 A marks; and “readers” (YTHDF1/2/3 and YTHDC1/2) that recognize m 6 A-modified RNA to regulate RNA…”
Self-citationRadiotherapy and immunotherapy: a beneficial liaison?
Weichselbaum, R. R., Liang, H., Deng, L., & Fu, Y.-X. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.211 · Cited by 1,070
Self-citationAnti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells
Han, D., Liu, J., Chen, C., Dong, L., Liu, Y., Chang, R., Huang, X., Liu, Y., Wang, J., Dougherty, U., et al. (2019) · Nature · doi:10.1038/s41586-019-0916-x · Cited by 955 · cited 2×
“50 53–55 However, the intrinsic role of YTHDF2 in immune cells especially in relation to radiotherapy and immunotherapy has not been explored in depth.”
Self-citationRadiotherapy induces responses of lung cancer to CTLA-4 blockade
Formenti, S. C., Rudqvist, N.-P., Golden, E., Cooper, B., Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Friedman, K., Ferrari de Andrade, L., Wucherpfennig, K. W., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0232-2 · Cited by 928
Burnette, B. C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N. N., Weichselbaum, R. R., Fu, Y.-X., & Auh, S. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2820 · Cited by 878
Self-citationKo, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862
The role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788 · cited 1×
“16,17 Mechanisms of immune suppression by MDSCs include secretion or expression of immunoregulatory factors, 18,19 which downregulate cytotoxic CD8 + T cell function.”
Cytoplasmic m6A reader YTHDF3 promotes mRNA translation
Li, A., Chen, Y.-S., Ping, X.-L., Yang, X., Xiao, W., Yang, Y., Sun, H.-Y., Zhu, Q., Baidya, P., Wang, X., et al. (2017) · Cell Research · doi:10.1038/cr.2017.10 · Cited by 764
Self-citationLuke, J. J., Lemons, J. M., Karrison, T. G., Pitroda, S. P., Melotek, J. M., Zha, Y., Al-Hallaq, H. A., Arina, A., Khodarev, N. N., Janisch, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.2229 · Cited by 588
Self-citationAlshetaiwi, H., Pervolarakis, N., McIntyre, L. L., Ma, D., Nguyen, Q., Rath, J. A., Nee, K., Hernandez, G., Evans, K., Torosian, L., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aay6017 · Cited by 537 · cited 2×
“…data sets in the TCGA database with MDSCs gene signature (ARG1, CD14, CD44, CD40, S100A8, SELPLG, STAT6, TFRC, TGFB2, STAT3, CD274, ITGA3, SLA, and KDR; 58 ) to investigate whether MDSC associated genes are increased in clinical samples post-RT and whether the increase correlates to poor outcome.”
Interleukin-10 Signaling Blocks Inhibitor of κB Kinase Activity and Nuclear Factor κB DNA Binding
Schottelius, A. J. G., Mayo, M. W., Sartor, R. B., & Baldwin, A. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.31868 · Cited by 532 · cited 1×
“76 We hypothesize that IL-10 may act in a negative feedback loop to regulate NF-κ B in an YTHDF2 dependent manner, as a part of intricate network of biological responses to inflammation.”
Paris, J., Morgan, M., Campos, J., Spencer, G. J., Shmakova, A., Ivanova, I., Mapperley, C., Lawson, H., Wotherspoon, D. A., Sepulveda, C., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.03.021 · Cited by 502
Halama, N., Zoernig, I., Berthel, A., Kahlert, C., Klupp, F., Suarez-Carmona, M., Suetterlin, T., Brand, K., Krauss, J., Lasitschka, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.005 · Cited by 495
Host STING-dependent MDSC mobilization drives extrinsic radiation resistance
Liang, H., Deng, L., Hou, Y., Meng, X., Huang, X., Rao, E., Zheng, W., Mauceri, H., Mack, M., Xu, M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01566-5 · Cited by 488 · cited 3×
“21 In pre-clinical studies, both fractionated and hypo-fractionated treatment regimens resulted in MDSC expansion, 22–25 which lead to tumor radioresistance 24,26,27 .”
Self-citationMyeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Dixit, D., Prager, B. C., Gimple, R. C., Poh, H. X., Wang, Y., Wu, Q., Qiu, Z., Kidwell, R. L., Kim, L. J. Y., Xie, Q., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0331 · Cited by 410 · cited 1×
“42,44 45–49 Only few studies have reached the impact of reader proteins on antitumor immune response: loss of Ythdf1 enhanced the cross-priming activity via decreasing lysosomal proteases in classical dendritic cells and suppressed tumor growth.”
Ionizing radiation induces expression and binding activity of the nuclear factor kappa B.
Brach, M. A., Hass, R., Sherman, M. L., Gunji, H., Weichselbaum, R., & Kufe, D. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115354 · Cited by 408
Self-citationZhu, T., Roundtree, I. A., Wang, P., Wang, X., Wang, L., Sun, C., Tian, Y., Li, J., He, C., & Xu, Y. (2014) · Cell Research · doi:10.1038/cr.2014.152 · Cited by 373 · cited 1×
“The cloned Ythdf2 cDNA with K416A, R527A, W432A, and W486A mutation, which has been proved to significantly decrease the m 6 A binding affinity 80 , were synthesized and cloned into the lentiviral expression vector pLVX-ZsGreen-N1 to generate pLVX-ZsGreen-N1-YTHDF2-Mut (GenScript).”
Self-citationTranscriptional regulation of myeloid-derived suppressor cells
Condamine, T., Mastio, J., & Gabrilovich, D. I. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.4ri0515-204r · Cited by 372 · cited 1×
“70 Thus our data indicate that IR induces YTHDF2 via NF-κ B, and the elevated YTHDF2 levels may in turn enhance NF-κ B signaling in MDSCs, thus forming an IR-YTHDF2-NF-κ B circuit.”
TIPE2, a Negative Regulator of Innate and Adaptive Immunity that Maintains Immune Homeostasis
Sun, H., Gong, S., Carmody, R. J., Hilliard, A., Li, L., Sun, J., Kong, L., Xu, L., Hilliard, B., Hu, S., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.026 · Cited by 369
Self-citationYTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma
Hou, J., Zhang, H., Liu, J., Zhao, Z., Wang, J., Lu, Z., Hu, B., Zhou, J., Zhao, Z., Feng, M., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1082-3 · Cited by 361
Self-citationYthdf2-mediated m6A mRNA clearance modulates neural development in mice
Li, M., Zhao, X., Wang, W., Shi, H., Pan, Q., Lu, Z., Perez, S. P., Suganthan, R., He, C., Bjørås, M., et al. (2018) · Genome Biology · doi:10.1186/s13059-018-1436-y · Cited by 353
Self-citationIclozan, C., Antonia, S., Chiappori, A., Chen, D.-T., & Gabrilovich, D. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1396-8 · Cited by 317 · cited 1×
“38 Despite these studies, no randomized trials have shown improved survival.”
Cancer Stem Cells and Radioresistance: DNA Repair and Beyond
Schulz, A., Meyer, F., Dubrovska, A., & Borgmann, K. (2019) · Cancers · doi:10.3390/cancers11060862 · Cited by 303 · cited 1×
“3 The immune contexture is vital in radiocurability.”
Non-canonical NF-κB Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy
Hou, Y., Liang, H., Rao, E., Zheng, W., Huang, X., Deng, L., Zhang, Y., Yu, X., Xu, M., Mauceri, H., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.07.008 · Cited by 265 · cited 1×
“63 Further investigation of the relationship between NF-κ B and YTHDF2 revealed that the level of nuclear RELA is increased after IR (Figure S4E).”
Self-citationLiauw, S. L., Connell, P. P., & Weichselbaum, R. R. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005148 · Cited by 257
Self-citationSuppression of m6A reader Ythdf2 promotes hematopoietic stem cell expansion
Li, Z., Qian, P., Shao, W., Shi, H., He, X. C., Gogol, M., Yu, Z., Wang, Y., Qi, M., Zhu, Y., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0072-0 · Cited by 257 · cited 1×
“50 53–55 However, the intrinsic role of YTHDF2 in immune cells especially in relation to radiotherapy and immunotherapy has not been explored in depth.”
Self-citationHesser, C. R., Karijolich, J., Dominissini, D., He, C., & Glaunsinger, B. A. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1006995 · Cited by 193
Self-citationMetrnl: A secreted protein with new emerging functions
Zheng, S.-L., Li, Z.-Y., Song, J., Liu, J.-M., & Miao, C.-Y. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.9 · Cited by 190
Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Califano, J. A., Khan, Z., Noonan, K. A., Rudraraju, L., Zhang, Z., Wang, H., Goodman, S., Gourin, C. G., Ha, P. K., Fakhry, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1716 · Cited by 184 · cited 1×
“…(20 trials using CCR5/CCR2 antagonists and 52 trials using CSFR antagonists), 36 MDSC function blockage to attenuate their suppressive effects (targeting phosphodiesterase 5 to reduce iNOS and ARG1 production), 37 and induction of MDSC differentiation by utilizing all-trans-retinoic acid (ATRA).”
Negative regulation of cytokine signaling and immune responses by SOCS proteins.
Yoshimura, A., Nishinakamura, H., Matsumura, Y., & Hanada, T. (2005) · Arthritis Research · doi:10.1186/ar1741 · Cited by 182 · cited 1×
“…“negative regulation of inflammatory response” pathway in Ythdf2-cKO+IR (Figure S5A), containing five genes (Tnfaip8l2, Socs3, Smpdl3b, Metrnl and Adrb2) which have been reported as negative regulators for NF-κ B signaling, 65–69 which facilitates MDSC migration and chemokine/ cytokine regulation.”
Lin, Y., Cao, Y., Kim, H. J., Salim, A., Speed, T. P., Lin, D. M., Yang, P., & Yang, J. Y. H. (2020) · Molecular Systems Biology · doi:10.15252/msb.20199389 · Cited by 174
Radiotherapy and immunotherapy: open questions and future strategies
Pointer, K. B., Pitroda, S. P., & Weichselbaum, R. R. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.003 · Cited by 173 · cited 1×
“4 9 Encouraged by these promising preclinical results, an increasing number of clinical trials combining checkpoint blockade with IR has been launched (reviewed in 10,11 ).”
Self-citationDynamic RNA Modifications in Posttranscriptional Regulation
Wang, X., & He, C. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.09.001 · Cited by 162
Self-citationBestvina, C. M., Pointer, K. B., Karrison, T. G., Al‐Hallaq, H., Hoffman, P. C., Jelinek, M. J., Juloori, A., Melotek, J. M., Murgu, S. D., Partouche, J., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.019 · Cited by 161 · cited 3×
“Pembro-SBRT study (NCT02608385) and COSINR study (NCT03223155): The studies and amendments were approved by the University of Chicago Biological Sciences Division institutional review board (IRB15-1130 and IRB17-0547, respectively).”
InfluentialSelf-citationMETTL3/YTHDF2 m 6 A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer
Xie, H., Li, J., Ying, Y., Yan, H., Jin, K., Ma, X., He, L., Xu, X., Liu, B., Wang, X., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15063 · Cited by 155
Targeting the NF-κB Pathway in Cancer Therapy
Erstad, D. J., & Cusack, J. C. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.011 · Cited by 152
Dichotomous engagement of HDAC3 activity governs inflammatory responses
Nguyen, H. C. B., Adlanmerini, M., Hauck, A. K., & Lazar, M. A. (2020) · Nature · doi:10.1038/s41586-020-2576-2 · Cited by 150
Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients
van Meir, H., Nout, R. A., Welters, M. J. P., Loof, N. M., de Kam, M. L., van Ham, J. J., Samuels, S., Kenter, G. G., Cohen, A. F., Melief, C. J. M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1267095 · Cited by 143
Mapperley, C., van de Lagemaat, L. N., Lawson, H., Tavosanis, A., Paris, J., Campos, J., Wotherspoon, D., Durko, J., Sarapuu, A., Choe, J., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20200829 · Cited by 141
Wang, H., Zuo, H., Liu, J., Wen, F., Gao, Y., Zhu, X., Liu, B., Xiao, F., Wang, W., Huang, G., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0082-y · Cited by 137 · cited 1×
“50 53–55 However, the intrinsic role of YTHDF2 in immune cells especially in relation to radiotherapy and immunotherapy has not been explored in depth.”
Ghosh, S., Huang, J., Inkman, M. J., Zhang, J., Thotala, S., Tikhonova, E., Miheecheva, N., Frenkel, F. E., Ataullakhanov, R. I., Wang, X., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn6758 · Cited by 117
Notch-mediated lactate metabolism regulates MDSC development through the Hes1/MCT2/c-Jun axis
Zhao, J., Ye, Y., Gao, C.-C., Wang, L., Ren, K., Jiang, R., Hu, S., Liang, S.-Q., Bai, J., Liang, J.-L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110451 · Cited by 108 · cited 1×
“16,17 Mechanisms of immune suppression by MDSCs include secretion or expression of immunoregulatory factors, 18,19 which downregulate cytotoxic CD8 + T cell function.”
Self-citationThe Lipid-Modifying Enzyme SMPDL3B Negatively Regulates Innate Immunity
Heinz, L. X., Baumann, C., Köberlin, M. S., Snijder, B., Gawish, R., Shui, G., Sharif, O., Aspalter, I. M., Müller, A. C., Kandasamy, R. K., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.05.006 · Cited by 103
Takenaka, M. C., Araújo, L. P., Maricato, J. T., Nascimento, V. M., Guereschi, M. G., Rezende, R. M., Quintana, F. J., & Basso, A. S. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501206 · Cited by 102
YTHDF2 promotes mitotic entry and is regulated by cell cycle mediators
Fei, Q., Zou, Z., Roundtree, I. A., Sun, H., & He, C. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000664 · Cited by 99
Self-citationColton, M., Cheadle, E. J., Honeychurch, J., & Illidge, T. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01678-1 · Cited by 98 · cited 1×
“15 In the setting of cancer, MDSCs maintain cellular plasticity and can be reprogrammed into various myeloid cells depending on the tumor, normal tissue microenvironments as well as various treatments.”
Lin, L., Kane, N., Kobayashi, N., Kono, E. A., Yamashiro, J. M., Nickols, N. G., & Reiter, R. E. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2293 · Cited by 95
Myeloid-Derived Suppressor Cells and Radiotherapy
Jiménez‐Cortegana, C., Galassi, C., Klapp, V., Gabrilovich, D. I., & Galluzzi, L. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-1105 · Cited by 93 · cited 2×
“16,17 Mechanisms of immune suppression by MDSCs include secretion or expression of immunoregulatory factors, 18,19 which downregulate cytotoxic CD8 + T cell function.”
Sridharan, V., Margalit, D. N., Lynch, S. A., Severgnini, M., Zhou, J. M., Chau, N. G., Rabinowits, G., Lorch, J. H., Hammerman, P. S., Hodi, F. S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.166 · Cited by 92
Chen, M., Qiao, G., Hylander, B. L., Mohammadpour, H., Wang, X.-Y., Subjeck, J. R., Singh, A. K., & Repasky, E. A. (2020) · Nature Communications · doi:10.1038/s41467-020-15676-0 · Cited by 92 · cited 1×
“65,74,75 We cannot rule out the possibility that these three proteins may target additional signaling involved in the regulation of MDSC suppressive functions.”
Wang, D., An, G., Xie, S., Yao, Y., & Feng, G. (2016) · Tumor Biology · doi:10.1007/s13277-016-4916-2 · Cited by 74
Tsai, M.-S., Chen, W.-C., Lu, C.-H., & Chen, M.-F. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.02.027 · Cited by 70 · cited 1×
“33 There are several ongoing or recently completed phase 1/2 clinical trials aiming to modulate MDSCs to enhance immunotherapy in distinct ways.”
The Impact of Radiation Therapy on Innate and Adaptive Tumor Immunity
Brandmaier, A., & Formenti, S. C. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.005 · Cited by 68
Jung, T. W., Pyun, D. H., Kim, T. J., Lee, H. J., Park, E. S., El‐Aty, A. M. A., Hwang, E. J., Shin, Y. K., & Jeong, J. H. (2021) · Advances in Medical Sciences · doi:10.1016/j.advms.2021.01.007 · Cited by 63
Oweida, A. J., Mueller, A. C., Piper, M., Milner, D. C., Court, B. V., Bhatia, S., Phan, A. V., Bickett, T. E., Jordan, K. R., Proia, T. A., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02701-w · Cited by 48 · cited 1×
“21 In pre-clinical studies, both fractionated and hypo-fractionated treatment regimens resulted in MDSC expansion, 22–25 which lead to tumor radioresistance 24,26,27 .”
Myeloid-cell differentiation redefined in cancer
Wynn, T. A. (2013) · Nature Immunology · doi:10.1038/ni.2539 · Cited by 41
Turchan, W. T., Pitroda, S. P., & Weichselbaum, R. R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0145 · Cited by 37 · cited 1×
“4 9 Encouraged by these promising preclinical results, an increasing number of clinical trials combining checkpoint blockade with IR has been launched (reviewed in 10,11 ).”
Self-citationIchim, C. V., Atkins, H. L., Iscove, N. N., & Wells, R. A. (2011) · Leukemia · doi:10.1038/leu.2011.137 · Cited by 31
Standard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer
Yazdi, M. T., Schinkelshoek, M. S., Loof, N. M., Taube, C., Hiemstra, P. S., Welters, M. J. P., & van der Burg, S. H. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1255393 · Cited by 31
Fu, S., Chen, G. T. Y., Wang, C., Yu, C., Chiang, C., & Hong, J. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.11.004 · Cited by 25 · cited 1×
“21 In pre-clinical studies, both fractionated and hypo-fractionated treatment regimens resulted in MDSC expansion, 22–25 which lead to tumor radioresistance 24,26,27 .”
Searle, E. J., Telfer, B. A., Mukherjee, D., Forster, D. M., Davies, B. R., Williams, K. J., Stratford, I. J., & Illidge, T. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707767 · Cited by 17 · cited 1×
“4 9 Encouraged by these promising preclinical results, an increasing number of clinical trials combining checkpoint blockade with IR has been launched (reviewed in 10,11 ).”
Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer
Haughey, C. M., Mukherjee, D., Steele, R. E., Popple, A. L., Dura-Perez, L., Pickard, A., Patel, M., Jain, S., Mullan, P. B., Williams, R. D., et al. (2020) · Cancers · doi:10.3390/cancers12102804 · Cited by 16 · cited 1×
“21 In pre-clinical studies, both fractionated and hypo-fractionated treatment regimens resulted in MDSC expansion, 22–25 which lead to tumor radioresistance 24,26,27 .”
Cited by
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Metadata
- Authors
- Wang, L., Dou, X., Chen, S., Yu, X., Huang, X., Zhang, L., Chen, Y., Wang, J., Yang, K., Bugno, J., Pitroda, S., Ding, X., Piffko, A., Si, W., Chen, C., Jiang, H., Zhou, B., Chmura, S. J., Luo, C., Liang, H. L., He, C., & Weichselbaum, R. R.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2023-07
- Volume
- 41
- Issue
- 7
- Pages
- 1294-1308.e8
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W4378213792
- Cited by
- 246
- References
- 89
- FWCI
- 25.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.